Gain Therapeutics Inc
NASDAQ:GANX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gain Therapeutics Inc
NASDAQ:GANX
|
US |
|
F
|
Fairchild Gold Corp
XTSX:FAIR
|
CA |
|
N
|
Nova Net Lease REIT
CNSX:NNL.U
|
CA |
Gain Therapeutics Inc
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2021-03-18. The Company, through its subsidiary, GT Gain Therapeutics SA, is a development stage biotechnology company. The firm is focused on developing therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. The company uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which are small molecules with the potential to treat diseases with unmet medical need. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2021-03-18. The Company, through its subsidiary, GT Gain Therapeutics SA, is a development stage biotechnology company. The firm is focused on developing therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. The company uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which are small molecules with the potential to treat diseases with unmet medical need. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.
